Abstract
Comparative study on in vitro evaluations (hardness, friability, weight variation, assay, disintegration, and dissolution tests) of marketed pantoprazole tablets (2 batches of each) from WHO GMP certified Nepalese companies (encoded with BP-02-A1, BP-02-A2), non-GMP certified Nepalese companies (encoded with BP-02-B1, BP-02-B2), and multinational companies (encoded with BP-02-C1, BP-02-C2) were done. The result of hardness, friability, weight variation, and assay and disintegration tests of all marketed products comply with pharmacopoeial limit. However, BP-02-A2 showed the fastest disintegration. Moreover, the comparison of percentage drug release of these companies on the basis of dissolution study demonstrated that BP-02-A2 (90 % drug release) complied best with standard RDRL protocol while BP-02-B2 (78% drug release) does not comply with above specification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Kathmandu University Journal of Science, Engineering and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
